相关临床试验
138
14 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
10
7.3%
Available
1
0.7%
已完成
107
77.5%
Enrolling By Invitation
2
1.4%
尚未招募
2
1.4%
招募中
8
5.8%
终止
7
5.1%
撤回
1
0.7%
暂无批准数据
- Idorsia has entered an exclusive distribution agreement with Pharmalink for QUVIVIQ (daridorexant) across five Gulf Cooperation Council countries including UAE, Kuwait, Qatar, Oman, and Bahrain. - QUVIVIQ represents a novel dual orexin receptor antagonist that targets overactive wake signaling without broadly suppressing brain activity, offering an alternative to traditional hypnotics. - Clinical trials published in The Lancet Neurology demonstrated significant improvements in sleep onset, maintenance, and daytime functioning at both 25mg and 50mg doses compared to placebo. - The partnership leverages Pharmalink's established infrastructure of over 1,800 employees and 200+ pharmacies to address the high prevalence of insomnia in the GCC region.
- Idorsia's dual orexin receptor antagonist has been awarded the inaugural Prix Galien Bridges Award in the "Best Biotechnology & Pharmaceutical Product" category for its breakthrough approach to treating insomnia disorder. - The drug represents the first and only dual orexin receptor antagonist approved in Europe for insomnia treatment, developed after more than 10 years of research involving the synthesis and characterization of over 25,000 compounds. - The treatment targets the orexin system to induce physiological sleep while maintaining rapid onset and sufficient duration to cover the entire night without morning carry-over effects. - Insomnia disorder affects an estimated 9.2% of Switzerland's working-age population and is characterized by overactive wake signals that impair both nighttime sleep and daytime functioning.
- Simcere Pharmaceuticals has launched QUVIVIQ (daridorexant) in China, marking a significant milestone in the global expansion of Idorsia's dual orexin receptor antagonist for insomnia treatment. - The drug received approval without psychotropic drug control labeling, differentiating it from traditional sleep medications that are associated with dependence risks and next-day drowsiness. - Clinical trials published in The Lancet Neurology demonstrated that 25mg and 50mg doses significantly improved sleep onset, maintenance, and daytime functioning compared to placebo at months 1 and 3. - QUVIVIQ is now commercially available in 15 countries including the US, EU, Japan, and China, with Idorsia having received $80M in milestone payments from the licensing agreement.
- Analysis of FDA adverse event data reveals dual orexin receptor antagonists (DORAs) have only 2.6% abuse-related adverse events, significantly lower than benzodiazepines (27.7%) and Z-drugs (15.3%). - The study examined over 10 years of FAERS database records, finding DORAs had markedly lower reporting odds ratios for abuse compared to widely prescribed sleep medications like trazodone and zolpidem. - Researchers suggest the Schedule IV classification of DORAs may overstate their abuse potential, potentially limiting access to effective insomnia treatments for chronic sufferers. - The findings support DORAs as a safer long-term treatment option for the approximately 12% of US adults affected by insomnia disorder.
- Idorsia has partnered with Stanford Hypertension Center and Duke Heart Center to launch IMPACT-HTN, a three-phase program aimed at standardizing treatment and generating real-world evidence for difficult-to-control hypertension patients. - The initiative will develop AI-powered digital tools including a care algorithm, personalized risk scoring system, and patient-facing platforms to improve identification and management of hypertension patients requiring multiple medications. - IMPACT-HTN represents the first program of its kind to systematically address care coordination challenges for patients with difficult-to-control hypertension, potentially transforming treatment protocols for the estimated 50% of U.S. adults affected by hypertension. - The collaboration will explore how newer treatments like Idorsia's TRYVIO (aprocitentan), the first systemic hypertension treatment targeting a new pathway in over 30 years, can be integrated into modernized care pathways.
- Simcere Pharmaceuticals has received approval from China's National Medical Products Administration for QUVIVIQ (daridorexant) to treat adult insomnia patients with difficulty falling asleep and/or maintaining sleep. - The approval was achieved in just 2.5 years from the initial licensing agreement signing, with QUVIVIQ receiving no psychotropic drug control labeling in China. - Idorsia will receive a $50 million approval milestone payment and up to $93 million in commercial milestones under the updated licensing agreement. - QUVIVIQ is now available to patients across North America, Europe, Japan, and China, establishing it as a truly global insomnia treatment brand.
- New clinical data reveals daridorexant effectively reduces wakefulness throughout the night while improving next-morning sleepiness and daytime functioning in patients with chronic insomnia disorder. - The dual orexin receptor antagonist demonstrated dose-dependent improvements in sleep maintenance, with greater effects seen in the second half of the night when patients typically struggle most with wakefulness. - A separate crossover trial showed daridorexant significantly increased total sleep time by 56.6 minutes and reduced nocturia episodes, with 74% of patients preferring the treatment over placebo.
- Aprocitentan, a dual endothelin receptor antagonist, demonstrated clinically meaningful and sustained blood pressure reductions in Black patients with resistant hypertension when added to existing antihypertensive regimens. - The drug significantly reduced proteinuria by approximately 65% at the 25mg dose in patients with micro- or macroalbuminuria, addressing a critical need in a population disproportionately affected by hypertension-related complications. - Published in Hypertension, the PRECISION study subgroup analysis highlights aprocitentan as the first approved treatment targeting the endothelin system, potentially preventing thousands of cardiovascular events in Black patients who often struggle to achieve blood pressure control.
- The US FDA has eliminated the Risk Evaluation and Mitigation Strategy (REMS) requirement for TRYVIO (aprocitentan), determining that standard labeling is sufficient to communicate safety information. - TRYVIO, a dual endothelin receptor antagonist, is the first new antihypertensive medication with a novel mechanism of action in over 40 years, capable of reducing systolic blood pressure by more than 15 mmHg. - The removal of REMS requirements simplifies prescribing for healthcare providers and improves access for patients with difficult-to-control hypertension, including those with chronic renal failure.
• Owkin has initiated ATLANTIS, a comprehensive patient data mining program partnering with 20 leading healthcare institutions across seven countries, set to conclude by May 2025. • The project will analyze data across 11 therapeutic areas, including seven oncology programs, three immunology and inflammation conditions, and Alzheimer's disease, utilizing Owkin's AI platform Owkin K. • This initiative aims to break down data silos by integrating diverse medical data sources, including health records, imaging, and diagnostic results, to accelerate drug discovery and development.
